Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
Aduro Biotech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases.
The company is developing ADU-S100, which is in Phase I dose escalation clinical trial and Phase Ib dose escalation clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase II clinical trial in combination with pembrolizumab, an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck.
It is also developing product candidates to prevent or control immune responses through the stimulator of interferon genes pathway.
In addition, the company is developing BION-1301, a fully blocking humanized monoclonal anti-APRIL antibody that is in Phase I clinical trial for IgA nephropathy; and CD27, a co-stimulatory receptor, which is in preclinical studies expressed on different immune cells, such as T-lymphocytes and natural killer cells.
It has collaboration agreements with Novartis Pharmaceuticals Corporation, Eli Lilly and Company, and Merck Sharp and DohmeB. V.; and license agreements with Karagen Pharmaceuticals, Inc., UC Berkeley, and Memorial Sloan Kettering Cancer Center.
The company was formerly known as Oncologic, Inc. and changed its name to Aduro Biotech, Inc. in June 2008.
Aduro Biotech, Inc. was founded in 2000 and is headquartered in Berkeley, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 3, 20 | -1.05 Increased by +8.70% | -0.95 Decreased by -10.53% |
| May 4, 20 | -0.45 Increased by +68.97% | -0.67 Increased by +32.84% |
| Mar 9, 20 | -1.20 Increased by +27.27% | -1.05 Decreased by -14.29% |
| Nov 7, 19 | -1.30 Increased by +10.34% | -1.16 Decreased by -12.07% |
| Aug 1, 19 | -1.15 Decreased by -270.97% | -0.91 Decreased by -26.37% |
| May 7, 19 | -1.45 Decreased by -417.86% | -0.95 Decreased by -52.63% |
| Feb 27, 19 | -1.65 Decreased by -385.29% | -1.16 Decreased by -42.24% |
| Oct 30, 18 | -1.45 Decreased by -339.39% | -1.56 Increased by +7.05% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 20 | 5.57 M Increased by +14.03% | -16.61 M Increased by +10.57% | Decreased by -298.08% Increased by +21.57% |
| Mar 31, 20 | 13.95 M Increased by +254.24% | -7.58 M Increased by +67.67% | Decreased by -54.30% Increased by +90.87% |
| Dec 31, 19 | 3.63 M Increased by +31.73% | -19.41 M Increased by +26.23% | Decreased by -534.41% Increased by +44.00% |
| Sep 30, 19 | 4.80 M Increased by +56.68% | -20.95 M Increased by +9.48% | Decreased by -436.59% Increased by +42.22% |
| Jun 30, 19 | 4.89 M Increased by +85.22% | -18.58 M Increased by +23.85% | Decreased by -380.07% Increased by +58.89% |
| Mar 31, 19 | 3.94 M Decreased by -40.58% | -23.43 M Decreased by -8.99% | Decreased by -594.90% Decreased by -83.42% |
| Dec 31, 18 | 2.76 M Decreased by -26.57% | -26.32 M Decreased by -0.72% | Decreased by -954.31% Decreased by -37.17% |
| Sep 30, 18 | 3.06 M Decreased by -19.27% | -23.15 M Increased by +5.60% | Decreased by -755.66% Decreased by -16.92% |